Click on headlines below to download research

Beyond PD-LID, a closer look at PD-psychosis
IRLAB Therapeutics | 08/04/2024

While IRLAB Therapeutics’ immediate focus is on advancing mesdopetam in levodopa-induced dyskinesia (PD-LID) following the recent green light from…

FDA thumbs up to mesdopetam’s Phase III plan
IRLAB Therapeutics | 25/03/2024

IRLAB Therapeutics has confirmed the FDA’s alignment with its proposed Phase III programme for mesdopetam in levodopa-induced dyskinesias (PD-LIDs),…

Mesdopetam’s potential highlighted in PD-psychosis
IRLAB Therapeutics | 20/03/2024

The recent scientific paper in Neurotherapeutics discusses the encouraging preclinical studies focused on the characterisation of the neurophysiological…